Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Organic Chemistry >  Amides >  Sincalide ammonium (Cholecystokinin octapeptide ammonium)

Sincalide ammonium (Cholecystokinin octapeptide ammonium)

Basic information Safety Supplier Related

Sincalide ammonium (Cholecystokinin octapeptide ammonium) Basic information

Product Name:
Sincalide ammonium (Cholecystokinin octapeptide ammonium)
Synonyms:
  • Sincalide ammonium (Cholecystokinin octapeptide ammonium)
  • Cholecystokinin octapeptide ammonium
  • Sincalide ammonium
  • SQ19844 ammonium
  • SQ19844 ammonium|||CCK-8 ammonium|||Cholecystokinin octapeptide ammonium
CAS:
70706-98-8
MF:
C49H65N11O16S3
MW:
1160.3
Mol File:
70706-98-8.mol
More
Less

Sincalide ammonium (Cholecystokinin octapeptide ammonium) Chemical Properties

form 
Solid
color 
White to off-white
More
Less

Sincalide ammonium (Cholecystokinin octapeptide ammonium) Usage And Synthesis

Uses

Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK[1][2][3].

in vivo

Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model[4].

Animal Model:MI rat model[4]
Dosage:50 μg/kg
Administration:i.p.; 50 μg/kg/d; for 4 weeks
Result:Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.

References

[1] Maher KA. Kinevac (sincalide for injection)/Squibb Diagnostics. Gastroenterol Nurs. 1991 Oct;14(2):98-100. DOI:10.1097/00001610-199110000-00008
[2] Ziessman HA. Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues. J Nucl Med Technol. 2019 Sep;47(3):210-212. DOI:10.2967/jnmt.119.226019
[3] Can Wang, et al. Protective effect of cholecystokinin octapeptide on angiotensin II-induced apoptosis in H9c2 cardiomyoblast cells. J Cell Biochem. 2020 Jul;121(7):3560-3569. DOI:10.1002/jcb.29639
[4] Can Wang, et al. Cholecystokinin octapeptide reduces myocardial fibrosis and improves cardiac remodeling in post myocardial infarction rats. Int J Biochem Cell Biol. 2020 Aug;125:105793. DOI:10.1016/j.biocel.2020.105793

Sincalide ammonium (Cholecystokinin octapeptide ammonium)Supplier

Hangzhou Peptidego Biotech Co.,Ltd.
Tel
0571-87213919
Email
Eric@peptidego.com
Nanchang Tianzhen Biotechnology Co., Ltd
Tel
13758194781 13173652190
Email
522013271@qq.com
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Hangzhou Sinoda Pharmaceutical Technology Co. LTD
Tel
0571-87213919 17306812703
Email
3007955328@qq.com
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com